Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Express Scripts
Argus Health
Mallinckrodt
Cerilliant
Accenture
Baxter
QuintilesIMS
AstraZeneca

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,536,206

« Back to Dashboard

Which drugs does patent 8,536,206 protect, and when does it expire?

Patent 8,536,206 protects DALIRESP and is included in one NDA.

This patent has thirty-two patent family members in twenty-seven countries.
Summary for Patent: 8,536,206
Title:Process for the preparation of roflumilast
Abstract: The invention relates to novel processes for the preparation of high-purity roflumilast.
Inventor(s): Kohl; Bernhard (Constance, DE), Mueller; Bernd (Constance, DE), Palosch; Walter (Rielasingen, DE)
Assignee: Takeda GmbH (Konstanz, DE)
Application Number:13/547,945
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,536,206
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 8,536,206

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms DALIRESP roflumilast TABLET;ORAL 022522-002 Jan 23, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS ➤ Try a Free Trial
Astrazeneca Pharms DALIRESP roflumilast TABLET;ORAL 022522-001 Feb 28, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,536,206

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03005245Mar 08, 2003

Non-Orange Book US Patents Family Members for Patent 8,536,206

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,470,791 Process for the preparation of roflumilast ➤ Try a Free Trial
8,618,142 Process for the preparation of roflumilast ➤ Try a Free Trial
8,604,064 Process for the preparation of roflumilast ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,536,206

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Croatia P20050399 ➤ Try a Free Trial
Hong Kong 1085480 ➤ Try a Free Trial
South Korea 20050106392 ➤ Try a Free Trial
Israel 168170 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
Federal Trade Commission
Cantor Fitzgerald
Queensland Health
QuintilesIMS
Johnson and Johnson
Medtronic
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.